Skip to main content
Arvee Laboratories (India) Limited logo

Arvee Laboratories (India) Limited — Investor Relations & Filings

Ticker · ARVEE ISIN · INE006Z01016 LEI · 33580075Q2EAWYCO4C50 National Stock Exchange of India Manufacturing
Open in API
Filings indexed 280 across all filing types
Latest filing 2026-05-19 Interim / Quarterly Rep…
Country IN India
Listing National Stock Exchange of India ARVEE

About Arvee Laboratories (India) Limited

http://arveelabs.com/

Arvee Laboratories (India) Limited specializes in the manufacturing and export of specialty chemicals and pharmaceutical intermediates. The company focuses on the production of high-quality chemical compounds, including Dimethyl 5-Sulfoisophthalate Sodium Salt (DMSIP), 5-Sulfoisophthalic Acid Monosodium Salt, and various other aromatic intermediates. These products serve as critical components in the textile, polymer, and pharmaceutical sectors. Arvee Laboratories emphasizes research and development to enhance its chemical synthesis processes and maintain international quality standards. Its operations involve complex chemical reactions such as sulfonation, esterification, and reduction, catering to a diverse global clientele requiring specialized chemical solutions for industrial applications.

Recent filings

Filing Released Lang Actions
Outcome of Board Meeting
Interim / Quarterly Report Classification · 85% confidence The document is a Board meeting outcome notice under SEBI LODR where Arvee Laboratories’ Board approves and publishes detailed audited financial results for the quarter and year ended March 31, 2026. It includes a full Statement of Assets & Liabilities, Statement of Audited Financial Results (quarterly and year), and a Cash Flow Statement. This is not a brief earnings summary (ER) nor the company’s full Annual Report (10-K), but a comprehensive financial report for the quarter (including year-end audited numbers). Therefore, it falls under Interim / Quarterly Report (IR). FY 2026
2026-05-19 English
Board Meeting — Financial Results/Other business matters
Regulatory Filings Classification · 95% confidence The document is a notification to the stock exchange about the postponement of a Board Meeting originally scheduled for May 18, 2026, due to lack of quorum. It mentions that the meeting is rescheduled to May 19, 2026, where among other matters, standalone audited financial results will be considered. The document does not contain any financial data or results itself, nor does it present any report. It is an announcement related to a board meeting schedule change and compliance with insider trading code. The document length is short (1521 characters), and it serves as an official notification rather than a report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-05-18 English
Price movement
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the National Stock Exchange of India Limited, providing a clarification on the movement in the company's share price. It references compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, and states that there are no material events requiring disclosure. The document is short (1474 characters) and is a regulatory response or clarification rather than a financial report or announcement of a report. It does not contain financial data, management discussion, or any detailed report content. It is not an earnings release, annual report, or any other detailed filing. It is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance documents that do not fit other categories.
2026-04-15 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to the National Stock Exchange of India Limited regarding the closure of the trading window for dealing in the company's securities. It specifies the dates for the trading window closure around the declaration of financial results for the period ended March 31, 2026. The content focuses on compliance with insider trading regulations and does not contain any financial data, report, or detailed announcement of results. It is an announcement related to trading restrictions rather than a financial report or management information. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2026-03-27 English
Price movement
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the National Stock Exchange of India Limited providing a clarification on the movement in the company's stock price. It references compliance with SEBI Listing Obligations and Disclosure Requirements but does not contain any financial data, report, or detailed analysis. The document is short (1462 characters) and serves as a regulatory communication rather than a financial report or announcement of a report. It does not fit into categories like Annual Report, Earnings Release, or any financial filings. It is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory communications that do not fit other specific categories.
2026-03-06 English
Outcome of Board Meeting
Regulatory Filings
2026-02-13 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.